Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer by Valdés-Mora, Fatima et al.
Boston University
OpenBU http://open.bu.edu
BU Open Access Articles BU Open Access Articles
2017-04-18
Clinical relevance of the
transcriptional signature regulated
by CDC42 in colorectal cancer
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version
Citation (published version): Fatima Valdés-Mora, Warwick J Locke, Eva Bandrés, David
Gallego-Ortega, Paloma Cejas, Miguel Angel García-Cabezas, Yolanda
Colino-Sanguino, Jaime Feliú, Teresa Gómez Del Pulgar, Juan Carlos
Lacal. 2017. "Clinical relevance of the transcriptional signature
regulated by CDC42 in colorectal cancer.." Oncotarget, Volume 8,
Issue 16, pp. 26755 - 26770.
https://hdl.handle.net/2144/28911
Boston University
Oncotarget26755www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 16), pp: 26755-26770
Clinical relevance of the transcriptional signature regulated by 
CDC42 in colorectal cancer
Fatima Valdés-Mora1,2, Warwick J. Locke3, Eva Bandrés4, David Gallego-Ortega2,5, 
Paloma Cejas6, Miguel Angel García-Cabezas7, Yolanda Colino-Sanguino1,2, Jaime 
Feliú6,8, Teresa Gómez del Pulgar6,*, Juan Carlos Lacal6,*
1Histone Variants Group, Epigenetics Research Program, Genomics and Epigenetics Division, Garvan Institute of Medical 
Research, Sydney, New South Wales, Australia 
2St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Sydney, New South Wales, Australia
3Epigenetics Research Program, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New 
South Wales, Australia
4Immunology Unit, Department of Haematology, Complejo Hospitalario de Navarra, Navarra Health Service, Pamplona, Spain
5Tumour Development Group, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, 
Australia
6Laboratorio de Oncología Translacional, Servicio de Oncología Médica, IdiPAZ, Madrid, Spain
7Servicio de Anatomía Patológica, Hospital Universitario La Paz, Madrid, Spain
8Servicio de Oncología Médica, IdiPAZ, CIBERONC, Madrid, Spain
*Co-senior authors
Correspondence to: Juan Carlos Lacal, email: jclacal10@gmail.com 
Fatima Valdes-Mora, email: f.valdesmora@garvan.org.au
Keywords: colorectal cancer, CACNA2D2, CDC42, tumor suppressor genes,  prognostic factor
Received: June 16, 2016    Accepted: February 20, 2017    Published: March 01, 2017
Copyright: Valdés-Mora et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
CDC42 is an oncogenic Rho GTPase overexpressed in colorectal cancer (CRC). 
Although CDC42 has been shown to regulate gene transcription, the specific molecular 
mechanisms regulating the oncogenic ability of CDC42 remain unknown. Here, we 
have characterized the transcriptional networks governed by CDC42 in the CRC 
SW620 cell line using gene expression analysis. Our results establish that several 
cancer-related signaling pathways, including cell migration and cell proliferation, are 
regulated by CDC42. This transcriptional signature was validated in two large cohorts 
of CRC patients and its clinical relevance was also studied. We demonstrate that three 
CDC42-regulated genes offered a better prognostic value when combined with CDC42 
compared to CDC42 alone. In particular, the concordant overexpression of CDC42 and 
silencing of the putative tumor suppressor gene CACNA2D2 dramatically improved the 
prognostic value. The CACNA2D2/CDC42 prognostic classifier was further validated 
in a third CRC cohort as well as in vitro and in vivo CRC models. Altogether, we show 
that CDC42 has an active oncogenic role in CRC via the transcriptional regulation of 
multiple cancer-related pathways and that CDC42-mediated silencing of CACNA2D2 
is clinically relevant. Our results further support the use of CDC42 specific inhibitors 
for the treatment of the most aggressive types of CRC.
INTRODUCTION
Colorectal cancer (CRC) is among the most 
commonly diagnosed cancers worldwide and one of the 
leading causes of cancer-related deaths for both males 
and females [1]. Despite the high resectability rate and a 
general improvement in therapy, nearly half of all patients 
with colorectal cancer still die of metastatic disease. 
This poor outcome underscores the need for new tools to 
facilitate better management of CRC. The identification 
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of robust prognostic factors able to identify critical 
events in the development and progression of CRC will 
be of particularly high value. Therefore, to identify these 
factors and for an optimal management of the disease, it is 
essential to elucidate the molecular events involved in the 
malignant transformation. 
CDC42, a member of the Rho family of GTPases, 
is involved in the regulation of critical cellular functions 
such as rearrangement of actin cytoskeleton, cell polarity, 
intracellular trafficking, cell-cycle regulation, cell fate 
determination and gene transcription [2]. Considering 
its key role in these diverse cellular processes, it is not 
surprising that aberrant activation of CDC42 can be 
oncogenic. To date no activating CDC42 mutations have 
been detected in human cancer, but CDC42 has been 
shown to be overexpressed in many different cancer types 
such as breast [3, 4], testicular cancer [5], head and neck 
squamous cell cancer [6], melanoma [7], colorectal cancer 
[8], and non-small cell lung cancer [9].
CDC42 has been implicated in tumor development 
and progression through the alteration of its different roles 
in a tissue-specific manner. We have previously reported 
the overexpression of CDC42 in human CRC specimens 
is associated with histopathological grade [8]. The pro-
oncogenic role of CDC42 in this tumor type has been 
further demonstrated in several independent studies, in 
which the overexpression or silencing of CDC42 either 
in vitro or in vivo showed oncogenic-phenotypic effects 
in different colorectal cancer cell lines and mouse models 
[10–12]. These studies have demonstrated that the 
oncogenic impact of CDC42 was due to its well-known 
regulatory roles in cellular migration [10, 11, 13, 14] and 
proliferation [13–16]. CDC42 has been demonstrated 
to regulate the transcription regulation of a specific set 
of genes, [17] including down-regulation of the tumor 
suppressor gene ID4 [8]. However, the role of CDC42 in 
global gene transcriptional regulation in cancer remains 
poorly understood. 
The aim of this work was the identification of new 
and clinically relevant genes and transcriptional networks 
regulated by CDC42 in CRC. To this end, we used our 
previously established cellular models for CDC42 gain 
or loss of function in the CRC SW620 cell line [8] to 
profile the transcriptional changes mediated by CDC42. 
We identified not only transcriptional networks related 
to functions already described for CDC42 but also novel 
functions like chromatin regulation or stem-cell-related 
roles. CDC42 transcriptional signature comprising 57 
genes was validated in two CRC cohorts from the The 
Cancer Genome Atlas (TCGA). We further studied the 
prognostic significance of this transcriptional signature 
and found that the combination of CDC42 expression with 
CACNA2D2, LARS2 or REG1CP were better prognostic 
identifiers than each gene alone. Particularly, the most 
significant combination was found between high CDC42 
and low CACNA2D2, this new prognostic classifier was 
further validated in a third CRC cohort as well as in vitro 
and in vivo CRC models. Thus, CDC42 is a useful novel 
tool as a prognostic factor and a therapeutic target in CRC.
RESULTS
Identification of CDC42-driven transcriptional 
network in SW620 cells
To address if CDC42 regulates oncogenic 
transcriptional networks in CRC we used our previously 
generated in vitro CRC cellular model [8] to perform gene 
expression arrays. 
This in vitro model consists on cell clones with 
the stable expression of the wild type form of CDC42 as 
well as the genetic interference of CDC42 expression by 
shRNA in the adenocarcinoma colorectal cell line SW620 
(Figure 1A). CDC42 overexpressing cells (CDC42ov) 
only showed a modest up-regulation compared to the 
parental cell line SW620 (Figure 1A and Supplementary 
Figure 1A), which already had high CDC42 basal levels 
compared to other CRC cell lines as well as to a primary 
colon fibroblast cell line, CCD-18Co (Supplementary 
Figure 1B). The cell clones generated for the genetic 
interference (CDC42 shRNA) reached between 40% 
(CDC42-i2, cell clone) and 70–85% (CDC42-i1 and 
CDC42-i3, cell clones) reduced protein expression 
(Figure 1A).
Figure 1B shows that the genetic down-regulation of 
CDC42 resulted in a significant reduction of tumor growth 
of the positive xenografts (see Supplementary Table 1 for 
tumor incidence) compared to the CDC42 wt1 or SW620 
control cell lines as previously shown in other CRC cell 
lines [10–12]. These results consolidate the use of this 
cellular system as a powerful tool for the study of the 
CDC42-driven oncogenic transcriptional signature in CRC.
Next we carried out comparative gene expression 
arrays analysis in these cellular models to identify 
differentially expressed genes between CDC42 
overexpressing cells and knock down clones. In total, 190 
putative CDC42 target genes were identified (including 
89 up-regulated and 101 down-regulated, Figure 1C and 
Supplementary Table 2). Gene Set Enrichment Analysis 
(GSEA) identified enrichment of GO terms relating to 
known CDC42 target pathways (Figure 1D, Top table), 
including cytoskeleton regulation and cell migration. 
Additionally, a role in epigenetic regulation by CDC42 
also appears to be significant (term: chromatin). GSEA 
using the C2-CP collection (curated gene sets-canonical 
pathways, Figure 1D, bottom panel and Supplementary 
Table 3) further supports the role of CDC42 in epigenetic 
regulation with enrichment of multiple polycomb related 
gene sets (H3K27ME3, EED, SUZ1 and PRC2 targets) as 
well as a role in stem-cell related functions. 
Complementary analyses using Ingenuity Pathway 
Analyses (IPA) identified “Cancer” as the most significant 
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disease related term involving CDC42-dependent 
transcriptional deregulation (Supplementary Figure 2 and 
Figure 3). In keeping with a role of CDC42 in cancer onset 
and progression cellular growth, proliferation and cancer 
related pathways were significantly altered by modulation 
of CDC42 levels. Additionally, a plethora of signaling 
pathways are affected by CDC42  (Supplementary 
Figures 2 and 3) with potential effects on a diverse 
range of physiological processes. The top five networks 
identified with known molecular interactions that included 
most of the selected genes were: 1) Cell-to-cell signaling 
and interaction, cardiovascular system development 
and function, embryonic development; 2) Digestive 
system development and function, organismal injury and 
Figure 1: In vivo and transcriptional features of SW620 cell clones with altered CDC42 expression. (A) Protein levels of 
CDC42 determined by Western blot analysis in the selected SW620 cell clones to perform microarray studies. Tubulin or GAPDH were used 
as loading controls. Densitometrical analysis (Densit) of relative amount of CDC42 in each cell line compared to expression in parental cell 
line that was set to 1.0 is shown. Please note that the Western blot for CDC42 ov was cropped from a Western blot containing other clones 
to show the selected clones. The original image of this Western blot is shown in Supplementary Figure 1A. (B) Tumor growth of SW620 
xenografts in athymic nude mice. A total of 106 cells of each cell line (CDC42-wt1, parental SW620 cell line, CDC42-i1 and CDC42-i3) 
were injected subcutaneously in each flank of nude mice. Tumor volumes were determined twice a week for 35 days (*significantly 
different from control on day 35, p-value = 0.010, and ***significantly different from control on day 35, p-value = 0.004). (C) Heatmap 
showing the 190 differentially expressed genes using a fold-change cut-off of 1.5 in both groups of cells overexpressing CDC42 (CDC42-
wt1 and CDC42-wt2) or with silenced CDC42 expression (CDC42-i1 and CDC42-i2) when compared to the parental SW620 cell line and 
then opposite differential expression between CDC42ov and CDC42i. (D) Gene Set Enrichment Analysis (GSEA) of the 190 differentially 
expressed genes. The upper panel shows GSEA analysis against the Molecular Signatures Database v4.0 (MSigDB) GO gene sets (C5)/
GO cellular component collection (p-value < 0.05) and the bottom panel shows the top ten gene sets against the curated gene sets (C2)/
canonical pathways collection ordered by count (number of genes from the 190 list included in each data set). See Supplementary Table 3 
for the full list.
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abnormalities, renal and urological disease; 3) Cell death 
and survival, embryonic development, cancer; 4) Cell-
to-cell signaling and interaction, developmental disorder, 
hereditary disorder; 5) Amino acid metabolism, small 
molecule biochemistry, cellular growth and proliferation. 
Thus, the role of CDC42 in colorectal tumorigenesis could 
be caused by its function in transcriptional regulation in 
key genes involved in oncogenic processes.
Validation of the CDC42-transcriptional 
signature in CRC patient samples
To further validate this CDC42-driven 
transcriptional signature in the context of colorectal 
cancer, we used RNAseq data for a total of 628 CRC 
patients from The Cancer Genome Atlas (TCGA) Rectum 
Adenocarcinoma (READ) and Colon Adenocarcinoma 
(COAD) datasets [18]. Patients were stratified according 
to their CDC42 mRNA levels.  The top and bottom tertiles 
(N = 418) were used to interrogate which of the 190 
genes found in SW620 cells were differentially expressed 
concordantly with CDC42 (Figure 1C). A total of 57 genes 
showed differential expression between CDC42 groups 
(adjusted p-value < 0.05, Figure 2A and Supplementary 
Table 4) in same direction as observed in the cell line 
array data. GSEA of these genes clearly revealed their 
involvement in cancer-related pathways (Figure 2B and 
Supplementary Table 5), including p53 targets, liver 
cancer proliferation signatures, and KRAS neoplastic 
transformation. Altogether, these findings identify the 
most significant genes that correlate with CDC42 in CRC 
globally and independently of the particularities of a single 
colorectal cell line. 
Prognostic value of CDC42-transcriptional 
signature
We next explored if this transcriptional signature 
offered any advantage over the prognostic value for 
CDC42. First we analyzed the prognostic capacity of 
CDC42 mRNA levels. Figure 2C shows that CDC42 
expression was not significantly associated with overall 
survival when the patients were segregated according 
to CDC42 levels (tertiles or median). Next, we took 
the 57 genes concordantly differentially expressed 
with CDC42 (Supplementary Table 4) in the 453 
TCGA CRC patients with sufficient clinical data and 
analyzed their prognosis value alone or in combination 
with CDC42. From this analysis, we found that the 
expression of three genes, CACNA2D2, LARS2 and 
REG1CP render improved prognostic value when 
combined with CDC42 (Figures 2D–2F), where in 
the case of LARS2 and REG1CP there was only a 
modest improvement. Figure 2D shows that patients 
with low levels of LARS1 and high levels of CDC42 
(n = 137) have worse prognosis than patients with any 
other combinations (p-value = 0.0987, right graph), this 
group was defined as “high risk group”, although this 
was only a trend and did not reach significance. The 
high risk group was able to predict prognosis better 
than using CDC42 alone (Figure 2C, p-value = 0.214) 
as well as LARS2 alone (Figure 2D left graph, p-value 
= 0.143). A similar scenario was found in the case of 
REG1CP, where a high risk group was defined as high 
REG1CP and high CDC42 and significantly predicted 
a worse prognosis for this group of patients (Figure 2E, 
left plot, p-value = 0.0143). This prognostic identifier 
showed a slight improvement compared with REG1CP 
levels alone (Figure 2E right graph, p-value = 0.0194), 
and in both cases this prediction was significant. The 
best improvement of the prognostic value was observed 
in CACNA2D2 gene; patients with a combination of high 
CDC42 and low CACNA2D2 had a significantly poorer 
prognosis (Figure 2F, right graph, p-value = 0.0298), while 
the levels of CACNA2D2 alone were not associated with 
prognosis (Figure 2D, left graph p-value = 0.748). 
Additionally, we found that the expression levels 
between CDC42 and CACNA2D2, LARS2 and REG1CP 
were significantly correlated in the tumor samples 
(Spearman’s correlation r = −0.2507655 and p-value = 
1.84e–10 for CACNA2D2; r = −0.2097521 and p-value 
1.207e–07 for LARS2 and r = 0.08323233 and p-value 
= 0.03705 for REG1CP) in agreement with our array data 
in SW620 cells.
CACNA2D2 is down-regulated in CRC and it is a 
better prognostic predictor when combined with 
CDC42
CACNA2D2 is a tumor suppressor gene in several 
types of cancer [19, 20], however its role in CRC or 
correlation with CDC42 has not been described yet. 
CACNA2D2 mRNA levels were analyzed in an array of CRC 
cell lines and compared to a primary colon fibroblast cell 
line, CCD-18Co (Figure 3A). We found that CACNA2D2 
was down-regulated in five out of 7 CRC cell lines (71%), 
supporting a potential role as TSG in this tumor type. 
In order to confirm the possible clinical relevance of 
CACNA2D2 and also its correlation with CDC42 in CRC, 
we validated our results in a independent third CRC cohort 
of 54 patients where we had previously analyzed CDC42 
protein levels [8] (Table 1 and Figure 3B). CACNA2D2 
mRNA expression was found to be significantly decreased 
in colorectal carcinomas when compared to their 
corresponding matched normal colon tissues for 33 of 
54 samples (61%) (Figure 3B and 3C, p-value < 0.0001). 
In addition, we found that higher down-regulation of 
CACNA2D2 was significantly correlated with the presence 
of lymphovascular invasion (p-value = 0.03, Figure 3D). 
Next, the role of CACNA2D2 as a prognostic factor 
in CRC patients was analyzed similarly as we did with 
the TCGA cohorts. Patients categorized by CACNA2D2 
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levels using the median did not show any relevance with 
prognosis (data not shown) as we previously observed in 
the other cohorts (Figure 2D, left graph). We then looked 
if CACNA2D2 prognostic significance improved when 
combined with CDC42. We found that only the patients 
of the poorest prognosis groups, Dukes’ C and D stages, 
Figure 2: Validation of CDC42-transcriptional signature in CRC patients from The Cancer Genome Atlas (TCGA) 
Rectum Adenocarcinoma (READ) and Colon Adenocarcinoma datasets (COAD). (A) Heatmap of expression represented as 
Z-score of the 57 genes found to be correlated with CDC42 in the patient samples. Patients (N = 628) were stratified according to CDC42 
expression levels and the top and bottom tertiles are shown in this heatmap. CDC42 expression levels are indicated in the first row (marked 
as a red rectangle). The top tertile is called “CDC42 HIGH” (red bar) and the bottom tertile is represented as “CDC42 LOW” (blue bar), 
this accounts for a total number of 418 patients. (B) Top ten gene sets from GSEA of the 57 differentially expressed genes analysis against 
the Molecular Signatures Database v4.0 GO gene sets against the curated gene sets (C2) /canonical pathways collection (p-value < 0.05) 
ordered by count. See Supplementary Table 5 for the full list. (C) Kaplan Meier (KM) plots for the overall survival analysis of 453 patients 
according to CDC42 levels. Left hand side (LHS) graph shows the survival curve stratifying the patients according to CDC42 tertiles (low, 
blue; mid, purple and high, red) and the right-hand side (RHS) plot according to CDC42 median (low, blue and red, high). Univariate and 
multivariate analysis were performed to evaluate the prognostic significance, and p-values from the multivariate analysis are shown in 
the graphs. A prognostic risk identifier was found in LARS2 (D), REG1CP (E) and CACNA2D2 (F) when combined with CDC42 levels. 
The LHS KM plots show the survival analyses for these genes alone where high levels are represented in red and low levels are blue. The 
high-risk groups (gray) were then identified by taking the intersect of the CDC42 high expression and LARS2 low expression (D) REG1CP 
high expression (E) and CACNA2D2 low expression (F) groups and compared to any other combination (green). P-values for multivariate 
analysis for each case are shown. 
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showed a significant improvement in the prognostic 
value when these two genes were combined (Figure 3E 
and Table 2). Patients with high CDC42 (> 1.5 fold) and 
low CACNA2D2 (lowest quartile, p25) showed poorer 
prognosis than the rest of the patients within the Dukes’ C 
and D stages, this group was defined as “high risk group” 
(HR4.68; 95% CI, 1.29–16.92; p-value = 0.019; Table 2). 
The statistical correlation between CDC42 and 
CACNA2D2 in the tumor samples was also investigated. 
Pearson’s correlation test and the non-parametric 
Spearman correlation rank or Kendall tau correlation 
tests showed no direct correlation between CDC42 and 
CACNA2D2 in the clinical samples (data not shown). This 
could be due to the small number of patients used in this 
cohort (n = 54 patients) compared to our TCGA cohort 
(N = 628), in which we did see a significant correlation. 
However, Cox regression analyses showed a significant 
interaction between CACNA2D2 and CDC42 in the 
outcome of patients with regional lymph node or distant 
metastasis with CDC42 overexpression and reduced 
expression of CACNA2D2 (p-value = 0.005), suggesting 
that these two molecular markers interact affecting the 
outcome of the patients. 
In conclusion, the combined analysis of 
CDC42 and CACNA2D2 expression levels provides a 
compelling tool for a better identification of patients at 
Table 1: Clinical and pathological characteristics of patients from the CDC42 CRC cohort
Median age: 70.5 years, range 48–86
Number of patients (%)
Gender
         Female 18 (33.3)
         Male 36 (66.7)
T
         T2 5 (9.3)
         T3 40 (74.1)
         T4 9 (16.7)
Grade
      Well/Moderately differentiated 40 (74.1)
      Poorly differentiated 14 (25.9)
Location
        Colon 41 (75.9)
        Rectum 13 (24.1)
Dukes Stage
         A 4 (7.4)
         B 26 (48.1)
         C 18 (33.3)
         D 6 (11.1)
Lymphovascular invasion
        No 19 (35.2)
        Yes 17 (31.5)
        NA 18 (33.3)
NA not available.
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higher risk of mortality, especially for CRC patients in 
later stage disease.
CDC42 regulates the expression of the putative 
tumor suppressor gene CACNA2D2 in SW620 
cells
In order to further validate CACNA2D2 as a 
transcriptional target downstream CDC42 in CRC, we next 
studied whether its transcriptional silencing was CDC42-
dependent in our in vitro SW620 cellular model (Figure 1).
First, we validated CACNA2D2 expression array 
data through qPCR (Figure 4A). Increased expression of 
CACNA2D2 gene was observed after CDC42 knock down, 
while CACNA2D2 expression in both SW620 control cell 
line and CDC42ov cells was similar (Figure 4A), most 
likely due to the modest increase in CDC42 expression 
when compared to the parental cell line. To further 
strengthen these findings, we attempted to rescue the 
CACNA2D2-low phenotype by transiently overexpressing 
CDC42 in the CDC42 shRNA transfectants (i1 
and i3) (Figure 4B and Supplementary Figure 4A). 
Figure 3: CACNA2D2 expression in CRC and prognostic value in a CRC validation cohort. (A) CACNA2D2 gene 
expression was analyzed by qPCR in seven CRC cell lines and compared to the primary colon fibroblast cell line CCD-18Co, the data was 
normalized with 18S and relative to CCD-18Co (Log10RQ). #ND: not detected, CACNA2D2 mRNA was not detected in this sample by 
qPCR. (B) CACNA2D2 mRNA expression (y-axis at the LHS) and CDC42 protein levels (y-axis at the RHS) in 54 CRC tumor samples 
are represented. CACNA2D2 and CDC42 expression levels are presented as the quantity of CACNA2D2 gene in each tumor sample, 
normalized to an endogenous reference, 18S for CACNA2D2 and the housekeeping protein GAPDH in the case of CDC42 and relative to its 
corresponding matched normal tissue for each patient. (C) Mean expression of CACNA2D2 gene in normal and tumor tissues (***p-value 
< 0.0001). Data are presented as mean × 107 ± SEM. (D) Mean expression of CACNA2D2 gene in tumor tissues according to presence 
of lymphovascular invasion. *, significantly different from no presence of invasion (p-value = 0.03). (E) Disease-specific survival of the 
patients according the new proposed classifier based on CACNA2D2 and CDC42 levels. Low risk group includes patients with Dukes´ C 
and D with low levels of CDC42 and moderate to high levels of CACNA2D2 and the high risk group corresponds to Dukes´ C and D patients 
with high levels of CDC42 and low levels of CACNA2D2.
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Overexpression of CDC42 was very high after 48h, and 
consequently a ~50% of down-regulation of CACNA2D2 
was observed (Figure 4B). 
We then explored the plausible molecular 
mechanism by which CDC42 controls CACNA2D2 mRNA 
expression. We have previously reported that CDC42 
is involved in the silencing of ID4 through promoter 
hypermethylation in the SW620 cellular model [8] and 
CACNA2D2 has been already suggested to be silenced 
through promoter DNA methylation [21, 22]. Therefore 
we tested if CDC42 is regulating this gene through an 
epigenetic mechanism. Analysis of the promoter region 
of CACNA2D2 by bisulfite clonal sequencing showed no 
differences in DNA methylation levels between CDC42 
overexpressing and CDC42 shRNA cells with all possible 
CpG sites unmethylated in all of the cases (Figure 4C) 
ruling out an epigenetic mechanism as the explanation by 
which CDC42 silenced CACNA2D2.
CDC42 regulates the expression of CACNA2D2 
in tumor xenografts
To further study the oncogenic link between the 
up-regulation of CDC42 and subsequent silencing of 
CACNA2D2 in vivo, we further characterized the tumor 
xenografts generated by CDC42 (Figure 1B) for CDC42 
and CACNA2D2 expression. First, we measured the 
protein expression levels of CDC42 in the tumor xenograft 
tissues (Figure 5A and Supplementary Figure 4B). 
Surprisingly, tumors derived from CDC42 shRNA cells 
exhibited CDC42 expression comparable to that of parental 
SW620 (representative examples shown in Figure 5A and 
Supplementary Figure 4B), suggesting that recovery of 
CDC42 expression is strictly required for tumor growth 
in vivo. Thus, we propose a sub-population of CDC42 
shRNA cells was able to re-express endogenous CDC42 
leading to tumor growth. Reactivation of CDC42 in the knock 
down cells is likely a major barrier to tumorigenesis and may 
account for the significant delay in tumor growth observed in 
these samples (Figure 1B). In the CDC42-wt1 group, CDC42 
expression was comparable to that of the parental cells 
(Figure 5A and Supplementary Figure 4B) and subsequently, 
no delay in tumor formation was observed. Altogether, these 
results suggest that high levels of CDC42 are critical for 
tumor generation and progression in vivo in CRC.
Next, CACNA2D2 mRNA levels were measured by 
qPCR in the generated tumors. As xenograft samples may 
contain an unknown mix of mouse and human cells, we 
assayed murine tissue contamination in our samples using 
a Taqman probe from the mouse-specific murine β-actin, 
and a housekeeping gene (Supplementary Figure 5A). Only 
residual levels of murine tissue were detected in xenograft 
samples when compared to a control xenograft derived 
from the mouse bladder cancer MBT2 cell line. These 
results demonstrated that our tumor samples were primarily 
represented by the injected human cell lines. Furthermore, 
a 100% human specificity was shown for the Taqman 
probe for human CACNA2D2 gene as no expression was 
observed in the mouse MBT2 cell line (Figure 5B). To 
adjust CACNA2D2 expression to the total amount of human 
content from the xenografts, we used the human-specific 
housekeeping gene PGK1 (Supplementary Figure 5B), which 
also showed 100% specificity to human. Thus it is unlikely 
that murine contamination is likely to confound our findings. 
CACNA2D2 normalized levels were determined in 
xenograft tissues from SW620, CDC42-wt1, CDC42-i1 
and CDC42-i3 tumors, along with the same cell 
lines prior injection (Figure 5C). Interestingly, when 
compared to CDC42 shRNA cells before injection, 
CACNA2D2 expression was down-regulated in the 
CDC42 shRNA derived tumors to levels comparable to 
the parental CDC42-wt1 cell lines before injection and 
their corresponding tumor samples (Figure 5C). This 
result is in accordance to the loss of CDC42 interference 
observed after the in vivo experiment (Figure 5A) and to 
the reversion of the oncogenic phenotype induced by the 
presence of CDC42 (Figure 4B).
Altogether these findings demonstrated that CDC42 
silences the TSG CACNA2D2 in SW620 cells in vitro and 
in vivo confirming a transcriptional molecular link between 
the tumorigenic effect of CDC42 and the silencing of the 
TSG CACNA2D2 in CRC observed in patients.
DISCUSSION
CDC42 is a small GTPase involved in multiple 
cellular functions whose aberrant expression or/and 
activity has been shown to be oncogenic in different 
cancer types [23, 24]. We have previously reported 
that CDC42 is overexpressed in colorectal cancer and 
Table 2: Uni-and multivariate analyses for disease-specific survival of Dukes´C and D patients
Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
T stage pT4 vs. pT3 3.93 1.37–11.28 0.011 0.637 0.37–1.10 0.106
Classifier 4.68 1.29–16.92 0.019 3.662 0.94–14.28 0.062
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silenced the TSG ID4 through an epigenetic mechanism 
[8]. Our results have been reinforced by recent studies 
showing that CDC42 activation promotes adhesion and 
invasion of CRC cells [10] and that incipient intestinal 
tumor cells activate CDC42 as a crucial step in malignant 
progression [12]. 
A better understanding of the biological 
characteristics of CRC could improve both the assessment 
of prognosis and the ability to predict response to 
treatments. Thus, the aim of the present study was to 
identify genes and pathways transcriptionally controlled 
by CDC42 with biological and clinical relevance in CRC. 
To that end, gene expression profiling of a colorectal 
cancer cell model with modulation of CDC42 levels has 
revealed the main networks in which this GTPase could 
be involved. Expression of 190 genes were significantly 
altered by CDC42. Both GSEA and IPA analysis 
demonstrated a significant impact on a broad range of 
Figure 4: Transcriptional regulation of CACNA2D2 by CDC42 in SW620 cells. (A) CACNA2D2 gene expression in our 
cellular model was determined by qPCR in the different stable cell lines and compared to the levels in the parental SW620 cell line by 
the 2−ΔΔCT method. The results are shown as Log10 of relative quantity (RQ) of CACNA2D2 in each cell line using control SW620 cells as 
reference. (B) LHS: CDC42 protein expression was determined by Western blot after transient overexpression of CDC42 (the original image 
of this Western blot is shown in Supplementary Figure 4A). Stable CDC42 interfering cell lines, i1 and i3, were transiently transfected 
with empty plasmid (Cont) or wild type form of CDC42 (CDC42) and CDC42 expression was determined at 48 h post-transfection. 
RHS: CACNA2D2 gene expression determined by qPCR after transient overexpression of CDC42 in i1 and i3 cell lines. Expression was 
normalized using 18S as reference. Data are presented as the quantity of CACNA2D2 expression in the CDC42-i1 and CDC42-i3 cell lines 
transiently overexpressing CDC42 (i1-CDC42 and i3-CDC42, respectively) relative to the expression in the lines transfected with the 
empty plasmid as controls (i1-cont and i3-cont, respectively). #p-value = 0.1, *p-value = 0.0001, N = 3. (C) Bisulfite sequencing analysis 
of CACNA2D2 promoter region. Bisulfite maps determined by direct sequencing of individual clones show the density of methylated CpG 
sites (black circles) and unmethylated CpG sites (white circles) at individual CpG residues. Virtually all sites were fully methylated when 
sequencing. CpGenome Universal Methylated DNA was used as positive control. Representative results of SW620 cells with silenced 
CDC42 expression (CDC42 shRNA) and cells overexpressing CDC42 (CDC42 ov) are shown.
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transcriptional networks related to cell migration and 
proliferation, in agreement with previously published work 
[10, 11, 13–16]. A plausible explanation is that CDC42 
may have a broad spectrum effect due to its ability to 
regulate critical transcription factors involved in signaling 
of some of these biological processes [25–28]. Different 
external signals can initiate CDC42 transduction cascades 
by triggering different kinases that ultimately activate 
transcription factors including STAT3 and 5a, NFκB, 
E2F, SRF, cMyc, AP-1, ATF2, ELK, Max and Chop 
that ultimately affect a broad spectrum of cell functions 
(reviewed in [17]). Most of these signaling pathways are 
affected in cancer. 
Interestingly, our analysis also identifies chromatin 
regulation by the polycomb group and stem-cell related 
functions as novel targets of CDC42. CDC42 has been 
previously associated with the histone methyltransferase 
and PRC2 member EZH2 in T-cells in the context of actin 
polymerization in the cytosol [29], so it is possible that 
CDC42 transcriptional network reflects changes related 
to the polycomb group due to this association in SW620 
cells. In addition, a role for CDC42 in self-renewal and 
Figure 5: CDC42 and CACNA2D2 expression in SW620 tumor xenografts. (A) Analysis of total CDC42 protein levels in 
xenograft tumors generated by our SW620 cellular model of CDC42 knock down (CDC42-i1 and CDC42-i3), CDC42 overexpression 
(CDC42-wt1) and parental SW620 as well as in the cell lines prior injection. Western blot images of immunoblots stained with CDC42 
and normalized using GAPDH as loading control. Three representative tumors (T1-T3) of each group are shown. The original images of 
these Western blots are shown in Supplementary Figure 4B. (B) Probe specificity for human CACNA2D2 gene was tested using a murine 
cell line (MBT2) as negative control and two different human cell lines (SW620 and CDC42-i1 clone). (C) CACNA2D2 gene expression 
was determined in the different tumor xenografts. CACNA2D2 expression levels in cell lines before injection are shown as reference. 
CACNA2D2 levels were normalized with the human-specific housekeeping gene PGK1. The results are shown as Log10 of relative quantity 
(RQ) of CACNA2D2 in each sample using control SW620 cell line as reference
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differentiation of adult intestinal stem cells has been 
previously reported [30]. In this study, conditional 
ablation of Cdc42 in the mouse intestinal epithelium 
resulted in the formation of large intracellular vacuolar 
structures containing microvilli in epithelial enterocytes, 
a phenotype reminiscent of human microvillus inclusion 
disease, characterized by severe nutrient deprivation. 
Concordantly, another study has shown that the inhibition 
of CDC42 blocks the formation of intestinal tumors and 
it is highly expressed in intestinal tumor stem cells [12]. 
Our newly discovered CDC42-transcriptional 
signature was next tested in 628 CRC patients, where 
we found that the expression of 57 genes correlated with 
CDC42 levels in the tumor samples in the same direction 
as seen in SW620 cells. GSEA showed that these genes 
were mostly related to cell proliferation pathways and 
KRAS neoplastic transformation. Approximately 30-
50% of colorectal tumors are known to have a mutated 
KRAS gene. So our results suggest that CDC42 oncogenic 
effect might be enhanced in the context of KRAS mutated 
tumors. Indeed SW620 CRC cell line has KRAS mutated 
and KRAS has been previously shown to signal its 
oncogenic effect through AKT and CDC42 [31, 32]. In 
conclusion the genes regulated by CDC42 in CRC account 
for its role in proliferation and could be dependent on 
KRAS mutation status. However further investigation is 
required to establish this relationship in CRC.
Altogether, our study supports an oncogenic role 
of CDC42 in CRC by the transcriptional deregulation of 
key genes and pathways involved in several cancer-related 
processes. 
While we have previously shown that high CDC42 
is associated with less differentiated tumors [8], its 
prognostic value had not been tested in CRC. CDC42 
levels in tumor samples did not correlate with prognosis, 
however we found that three genes have an improved 
prognostic value when combined with CDC42 status: 
LARS2, REG1CP and CACNA2D2. Inactivation of 
LARS2 (leucyl-tRNA synthetase in mitochondria) has 
been described in nasopharyngeal cancer cells [33], and 
dysregulation of aminoacyl-tRNA synthesis has also been 
widely linked to tumorigenesis [34], however this is the 
first report showing a transcriptional link between CDC42 
and LARS2 in CRC. REG1CP (Regenerating Family 
Member 1 Gamma) is a pseudogene and is affiliated 
with the long non-coding RNA class, its physiological 
function is still unknown, so to our knowledge this is the 
first report to show its transcriptional association with 
CDC42 and its significant correlation with prognosis 
in CRC. CACNA2D2 gene, a subunit of the voltage-
dependent calcium channel complex, is located in the 
3p21.3 chromosomal region, a known tumor suppressor 
gene cluster, that also includes LARS2 [35]. A reduced 
expression of CACNA2D2 has been described in lung 
cancer [36], gliomas [21], nasopharyngeal [22], head and 
neck squamous cell carcinoma [37] and cervical carcinoma 
[38]. Our study is the first report that demonstrates the 
direct effect of CDC42 on the transcriptional silencing of 
CACNA2D2 gene. Prognostic implications of CACNA2D2 
have been reported in head and neck squamous cell 
carcinoma [37] and cervical carcinoma [38]. Here we also 
describe for the first time the clinical relevance of this 
gene in colorectal cancer. The transcriptional correlation 
and clinical significance of these three genes with CDC42 
further supports our proposed novel role for CDC42 in the 
regulation of oncogenic transcriptional signatures in CRC. 
Among these three genes, CACNA2D2 showed 
the best correlation with CDC42 as well as the best 
improvement on the prognostic value when combined with 
CDC42, so we took this gene to perform further validation 
of its clinical relevance in a third CRC cohort as well as to 
further perform in vitro and in vivo studies its relationship 
with CDC42. Here we propose the combined use of 
CDC42 and CACNA2D2 as a new prognostic classifier. In 
this validation cohort, survival analysis was intentionally 
restricted to the subgroup of patients with Dukes´ C and 
D tumor, where a significant interaction between the 
expression of CDC42 and CACNA2D2 was found. This 
subgroup represents the most aggressive subgroup in 
which tumors show metastatic spread to lymph nodes or 
distant organs. A low risk group corresponding to patients 
whose tumors showed low levels of CDC42 and moderate 
to high levels of CACNA2D2 was identified. Thus, this 
new classifier allows the identification of a group of 
patients with a higher risk of death.
Contrary to what was found in the case of the 
TSG ID4 [8], CDC42-dependent CACNA2D2 silencing 
was not due to DNA hypermethylation of the promoter, 
suggesting that the reduced expression may be associated 
with other mechanisms such as polycomb-mediated 
repression, mutation of the promoter region or dysfunction 
of transcription factors. It has been recently shown that 
the activity of pro-survival factors downstream of CDC42, 
such as PAK1 is increased in CDC42-driven colorectal 
tumorigenesis [12, 39] and these cascade pathways can 
regulate transcription through transcription factors like 
NFκB [40] and STAT3 [41]. CDC42 is able to activate 
several transcription factors, such as STAT3, NFκB and 
SRF [25–28], thus it might be possible that CDC42 
controls the transcription of CACNA2D2 gene through 
those or different transcription factors. However further 
research is needed to identify the specific molecular 
players in this CDC42-mediated signaling pathway.
Here we show for the first time a new oncogenic 
feature of CDC42, which is its ability to regulate the 
transcription of genes and pathways biologically and 
clinically relevant in CRC. Thus, CDC42 could be used 
as a therapeutic target for selective colorectal cancer 
intervention. In fact, recently some specific small molecules 
have been developed that specifically inhibits CDC42 
[11, 42–44], providing a new means to study CDC42 and 
the cellular processes under its control. In keeping with the 
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results presented here, one of these molecules, AZA197 
suppressed primary colon cancer growth in vivo and 
prolonged survival in SW620 tumor xenografts, indicating 
the therapeutic potential of this inhibitor based on targeting 
CDC42 GTPase activity in colorectal cancer.  
MATERIALS AND METHODS
Cell lines and cellular model
The following colorectal cancer cell lines were 
used in this study: SW620, WiDr, HT-29, HCT116, RKO, 
COLO 201 and T84 and the primary colon fibroblast cell 
line CCD-18Co. All cell lines were purchased from the 
American Type Culture Collection (ATCC). All these cell 
lines were passaged for less than 6 months after receipt. 
ATCC routinely performs STR analysis on its human 
cell lines. The cell lines were grown in the following 
media: DMEM (Gibco) in the case of CCD-18Co, HT-
29, T84 and SW620 cells; EMEM (Gibco) for WiDr 
and RKO cells; RPMI (Gibco) for COLO 201 cells and 
McCoy´s 5A (ATCC) for HCT116 cells. All media were 
supplemented with 10% of Foetal Bovine Serum (FBS), 
2 mM de glutamine, 0.5 µg/ml de fungizone y 100 U/ml 
de penicillin-streptomycin (all from Gibco). 
The stable cellular model for the overexpression and 
knock down of CDC42 in SW620 cells has been previously 
reported [8]. Briefly, SW620 cells were transfected with 
Lipofectamine Plus Reagent (Invitrogen, Carlsbad, 
CA) according to the manufacturer´s instructions using 
pcDNA3B-wtCdc42 and pSUPER shRNA plasmids. SW620 
cell line was authenticated for the last time in May 2016 by 
GeneMapper v3.7 (Applied Biosystems). 
Tumour xenograft establishment
Six-week old female athymic BALB/c nude mice 
were obtained from Charles River Laboratories. Animals 
were inoculated subcutaneously with 1 × 106 cells in both 
flanks (eight animals per group, see also Supplementary 
Table 1). Tumor volumes were estimated twice a week 
and calculated as (length × width2)/2 using micrometer 
calipers. Thirty-five days later mice were euthanized, 
and tumor tissues were snap frozen in liquid nitrogen, 
and stored for future analysis. All animal procedures 
were approved by the Ethical Committee of Animal 
Experimentation (CEEA-CNB) of Centro Nacional de 
Biotecnologia (CNB-CSIC, Madrid, Spain) in accordance 
with national and international guidelines and with the 
Royal Decree (RD 1201/2005). Permit number: CEEA-
CNB: 080047.
Protein extraction from cell lines and tissues and 
Western blot
For protein analysis, cells were harvested, washed 
twice with ice-cold PBS, and incubated in ice-cold lysis 
buffer [50 mMTris-HCl (pH 7.5), 10 mM Na4P2O7, 50 mM 
NaF, 5 mM EDTA, 0.5% Triton X-100 (v/v), 0.5% sodium 
deoxycholate (w/v)] along with phosphatase and protease 
inhibitors.
In the case of xenograft samples, proteins were 
extracted from 30-50 mg frozen tissues. Samples were 
homogenized and lysed in ice-cold buffer containing 
25 mM HEPES (pH 7.5), 1.5 mM MgCl2, 0.2 mM EDTA, 
0.3 M NaCl, 20 mM β-glycerophosphate and 0.1% Triton 
X-100 (v/v) supplemented with phosphatase/protease 
inhibitors and benzonase. Nuclei and detergent-insoluble 
material were removed by centrifugation at 14,000 rpm for 
20 minutes at 4ºC. Protein concentration was determined 
with Bradford Assay (Bio-Rad, Hercules, CA).
CDC42 expression in cell lines and xenograft 
tissues was determined by Western blot as previously 
described [8] using specific monoclonal antibodies for 
CDC42 (BD Transduction Laboratories, Lexington, KY), 
Tubulin (Sigma Chemical Co) and GAPDH (Chemicon 
International Inc., Temecula, CA, USA).
Gene expression arrays and bioinformatic 
analysis
Differential gene expression induced through genetic 
manipulation of CDC42 levels in SW620 cell line was 
determined using Human19K Oligo Array from Center for 
Applied Genomics (University of Medicine of New Jersey). 
Microarrays hybridization protocol, signal detection 
and data normalization description have been previously 
reported [45]. The experiments were made using biological 
replicates (two different sets of clones for each genetic 
modification) and also experimental replicates (performing 
the whole microarrays twice). Specifically, genes 
differentially expressed were identified by using a fold-
change cut-off of 1.5 in both groups of cells overexpressing 
CDC42 (CDC42ov) or with silenced CDC42 expression 
(CDC42i) when compared to the parental SW620 cell 
line and then opposite differential expression between 
CDC42ov and CDC42i (Supplementary Table 2).
Gene Set Enrichment Analysis (GSEA) was 
performed against the Molecular Signatures Database 
v4.0 (MSigDB) curated gene sets (C2) and GO gene 
sets (C5) Collections [46]. Enrichment was assessed by 
hypergeometric testing as implemented in the R stats 
package.
Ingenuity Pathways analysis software (IPA, 
Ingenuity Systems, www.ingenuity.com) was used 
to integrate the most significant biological pathways 
regulated by CDC42. A list of 190 differentially expressed 
genes was created (p-value < 0.05, fold change > 1.5 
& < −1.5). This dataset containing gene identifiers and 
corresponding fold change was uploaded to define the 
functional networks of differentially expressed genes. The 
analysis of the 190 genes showed 24 genes of unknown 
function and the remaining 166 genes were further 
analyzed.
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Acquisition and survival analysis of the cancer 
genome atlas (TCGA) expression data
Processed RNA-seq data and clinical data for The 
Cancer Genome Atlas (TCGA) Rectum Adenocarcinoma 
(READ) and Colon Adenocarcinoma (COAD) [18] were 
obtained through the NIH Genomic Data commons data 
portal. Processed RNA-seq expression data was available 
for 628 tumors of which 460 had available clinical 
information. For the platform comparison between 
microarray and RNAseq data, Human19K Oligo Array 
annotation to ensemble gene ID was successful for 171 
genes out of the original 190 genes. Differential expression 
analysis was performed using processed HTSeq counts 
data in R using the package DESeq2 [47]. 
Survival analysis was performed on the set of 
patients that had available clinical information and were 
aged < 90 years, leaving 453 patients. Stratification 
of patients into high and low expression groups was 
performed using upper quartile normalized FPKM 
values (obtained from TCGA) such that high expression 
patients were defined as having gene expression above 
the cancer population median. The high-risk population 
was then identified by taking the intersect of the CDC42 
high expression and CACNA2D2 low expression, LARS2 
low expression and REG1CP high expression groups, 
respectively. Analysis of survival was performed using 
a Cox proportional hazards model as implemented in 
the R package survival [48, 49]. Analysis was performed 
with membership in high/low expression groups as the 
explanatory variable (univariate) and age, T classification, 
evidence of venous and or lymphatic invasion, gender, 
tumor type (Colon or Rectum) and stage (multivariate). 
Tumor stage was collapsed to just 2 categories of Stage 1 
& 2 and Stage 3.
Patient tissues and survival data from the 
CDC42 CRC cohort
Fresh-frozen tumor specimens from 57 colorectal 
adenocarcinomas were obtained from treatment naïve 
patients (36 men and 18 women) who underwent surgery 
at La Paz University Hospital of Madrid, between 2003 
and 2006. All specimens were snap-frozen in liquid 
nitrogen immediately after surgery for storage at −80ºC. 
This study was approved by the Ethics Committee of La 
Paz University Hospital and all patients gave informed 
consent. This patient cohort was previously used to 
analyze the expression levels of the protein CDC42 [8]. 
The CDC42 protein information has been also used in this 
study. 
The RNA from 54 patients of this cohort met the 
quality requirements to proceed for cDNA and qPCR 
analysis. Clinical and pathological variables were 
determined and are summarized in Table 1. All patients 
had information on age, sex, grade, tumor location and 
lymphovascular invasion. 
For the study of the prognostic classifier, an analysis 
based on disease-specific survival restricted to stage II 
and III tumors was performed. A new classifier was then 
developed to integrate the interaction of CDC42 high 
expression and CACNA2D2 low expression and allow 
a classification of patients in good or poor prognosis 
groups based on disease-specific survival restricted to 
Dukes´ C and D tumors. Survival curves of the patients 
in the different risk groups were compared using the 
Kaplan-Meier method and analyzed by the log-rank test. 
Cox proportional-hazards models were used to estimate 
survival distributions, hazard ratios and interaction 
analysis.
To evaluate if this new proposed classifier might 
constitute an independent prognostic factor, clinical and 
histopathological data were included in both univariate 
and multivariate Cox regression analyses. Only T stage 
was found significant in the univariate analysis and 
therefore used as covariate for the multivariate adjustment. 
The univariate associations between CACNA2D2 
gene expression and the different clinical-pathological 
parameters were assessed by means of the Mann-Whitney 
or Kruskal-Wallis tests. 
The statistical analyses were performed using SPSS 
software, version 19 (Inc, Chicago, Illinois).
Statistical analysis
Pearson’s correlation test and the non-parametric 
Spearman correlation rank or Kendall tau correlation tests 
were used to study the relationship between CDC42 and 
LARS2, REG1CP and CACNA2D2 results. 
All statistical analyses were two-sided and 
considered significant if p-value < 0.05.
RNA extraction from cell lines and tissues and 
qPCR
Total RNA was prepared from the cell lines using 
the RNeasy Mini kit (Qiagen, Hilden, Germany) and 
prepared from xenograft and patient tissues using Trizol® 
Reagent (Invitrogen) and cleaned up with RNeasy Mini 
kit (Qiagen) by following the manufacturer’s instructions. 
Total RNA from each sample was quantified by the 
Nanodrop ND 1000 and RNA integrity was assessed by 
standard electrophoresis on agarose gel. First strand cDNA 
was synthesized from 1 µg of total RNA using the High-
Capacity cDNA Archive Kit (Applied Biosystems) at 37ºC 
for 2 h. 
The expression of CACNA2D2 and CDC42 genes 
was quantified by real-time PCR. Each cDNA sample was 
analyzed in triplicate using the ABI PRISM 770 Sequence 
Detector (Applied Biosystems). 18S ribosomal RNA was 
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amplified as reference gene for cell lines and clinical 
tissues. For normalization in the case of xenograft tissues, 
PGK1 was used as reference gene and the contamination 
of murine tissue was determined after amplification of 
murine actin (Actb). Probes used for amplification were 
purchased from Applied Biosystems as Taqman Gene 
Expression Assays (CACNA2D2 Assay ID: Hs00195772_
m1; CDC42 Assay ID: Hs00741586_mH; 18S ribosomal 
RNA Assay ID: Hs99999901_s1; PGK1 Assay ID: 
Hs99999906_m1; Actb Assay ID: Mm00607939_s1). 
Relative quantification of gene expression was calculated 
with the 2-ΔΔCt method [50]. 
Bisulfite clonal sequencing of CACNA2D2 
promoter region
Genomic DNA extraction, bisulfite modification and 
sequencing protocols have been described previously [8]. 
A semi nested PCR for CACNA2D2 promoter region was 
performed. The first round of amplification was done in 
a 20 μl volume with 2 μl template and 1 µM F primer 
(5′-TTATTATTAAATTTGTGATTTTAGGTTTTAAG
TT-3′), 1 µM R primer (5′-TCCCTACAACGCTAACT
CCAAA-3′) and 2.5U AmpliTaq Gold polymerase 
(Applied Biosystems, Foster City, CA) for 30cycles at 
95˚C, 30 sec at 52˚C, and 1 min at 72˚C, followed by a 
10-min final extension at 72˚C. Of the first round of PCR, 
a 1 μl sample was used for the second, in a 50μl volume 
using the same conditions but containing 0.8μl of a nested 
F primer (5′-GTTTTTAAAAGGGTTATATATGTTTTT
GTT-3′) and 0.8 μl of the R primer used in the first 
round of PCR. CpGenomeTM Universal Methylated DNA 
(Chemicon International) was used as positive control of 
fully methylated human genomic DNA.
Transient transfection
For transient transfection, cells were seeded 
48 h before transfection at a density of 3.5 × 106 cells/well 
in 6-well plate and transfected with 2 µg of pcDNA3B-
wtCdc42 plasmid using Lipofectamine Plus reagent 
(Invitrogen) according to manufacturer´s recommendations. 
The cells were harvested 48 h post-transfection, and 
overexpression was assessed by Western blot analysis.
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